Orano Med’s Post

Guidelines

🔬 Unlock the Future of #ProstateCancer Imaging with #PSMA #PET/CT! 🧬 PSMA imaging is transforming how we diagnose and treat prostate cancer, with unprecedented sensitivity and specificity. The 2024 CANM PSMA Guidelines are now available, offering new insights and best practices that will shape the future of nuclear medicine. 🚀 From groundbreaking developments in PSMA-targeted radiopharmaceuticals to practical applications in clinical settings, this guideline is a must-read for healthcare professionals aiming to stay ahead in prostate cancer management. 💡 Join the conversation! Discover more at the #CANM2024 Conference in Montreal, where experts will dive deeper into PSMA imaging and its impact on patient care. Don't miss this chance to exchange ideas with leading professionals in the field. For more info: https://lnkd.in/gGgbiiSF 📄 Explore the full guidelines here: https://lnkd.in/eupDuqX7 🔗 #Share with your network to spread the word and stay at the forefront of nuclear medicine innovation! #CANM #NuclearMedicine #PSMAPET #ProstateCancer #MedicalImaging #CANM2024 #HealthcareInnovation

PanMediso Spotlight｜Theranostics（IF=12.4）：Alpha-Nuclide Radiation-Driven Bystander Effect | Professor Fei Yu's Team Recently, Professor Fei Yu's team published China's first preclinical study on alpha-nuclides 212Pb/212Bi, titled “Role of Damaged Mitochondrial Transfer in Alpha-Particle Generator 212Pb Radiation-Induced Bystander Effect” in Theranostics (IF=12.4). This study explores how radiation-induced damaged mitochondria act as signaling mediators, facilitating the bystander effect in cancer treatment. The research indicates that molecules in the ICCM may influence the fate of bystander cells, suggesting that indirect tumor cell damage can achieve a broader therapeutic impact. This effect enhances the efficacy of alpha-nuclide therapy in targeting tumor cells beyond the irradiated area, offering a promising approach for cancer treatment. We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health. #Nuclide #Theranostics #212Pb #212Bi #ICCM

September 24th is #WorldCancerResearchDay! World Cancer Research Day was established to promote research in the prevention, diagnosis and treatment of cancer. Today we celebrate the advances that have been made in the nuclear medicine and theranostics industry as a result of research, and are passionate about the work we do to advance novel radiopharmaceuticals for oncology. #TakeTheLead

To mark Nuclear Medicine and Molecular Imaging Week, #Ariceum celebrates its team and their contributions to developing novel #radiopharmaceuticals, a key component of #nuclearmedicine to visualize and treat #cancer. Radiopharmaceuticals are used in diagnostic imaging procedures to produce non-invasive images of organs and tissues and also to treat malignancies. The theme for this year is “See it. Believe it. Treat it." #lifesciences #biotech #ATT001 #ATT002 #oncology #radiopharmaceuticals #cancer

Exciting News in Targeted Radiotherapy! GlyTherix Ltd has signed a global clinical supply agreement with Eckert & Ziegler SE, a leader in isotopes for nuclear medicine. This collaboration will provide GMP-grade Lutetium-177 chloride for GlyTherix's clinical trials, aimed at treating aggressive cancers through innovative antibody radiopharmaceuticals. GlyTherix’s approach utilizes Lu-177 combined with an antibody targeting Glypican-1, a protein prevalent in several aggressive cancers, allowing for localized radiation treatment while protecting healthy tissue. Clinical trials are set to kick off in Australia in early 2025, followed by U.S. trials in 2026. Dr Brad Walsh, CEO of GlyTherix, emphasized the importance of this partnership in further strengthening their global supply network, ensuring high-quality isotopes are available for patients. Dr. Harald Hasselmann, CEO of Eckert & Ziegler, echoed this sentiment, expressing enthusiasm for supporting groundbreaking treatments. Together, we’re paving the way for the future of cancer therapy! Read the media release here: https://lnkd.in/grX2vSmW #TargetedTherapy #Lutetium177 #InnovationInHealthcare

🚗The logistics behind centrally produced, radiolabeled nuclear medicines with a short half-life are always a challenge, but we are happy to announce that our first HER2 PET tracers have been successfully labeled with Gallium-68 at the Brussels Imaging Pharmacy (BIP) and dispatched for use in our HERMIA Phase 2b clinical study. Working with short-lived radioisotopes demands precise logistical planning, and we couldn’t have done it without the dedication of all involved. A huge thank you to the teams at BIP, Isotopes Services International (ISI), and our clinical sites for making this possible!    🔬 About our HERMIA trial: The HERMIA (HER2 Targeted Molecular Imaging in mBC Using 68Ga-ABS011) trial aims to validate the potential of our 68Ga-ABS011 PET tracer in accurately determining the HER2 expression status. This could be a game-changer, providing clinicians with crucial information to make more informed treatment decisions for patients with metastatic breast cancer. 👀 Looking forward to the next steps in this innovative journey!     #IndividualizedTreatment #NuclearMedicine #Radiology #ClinicalTrials #HER2 #Diagnostics 

Cancer

Could a new Theranostic Pair be on the rise? It's not surprising, really -- given the money, time, and resources that have been poured into Nuclear Medicine. However, what is pretty exciting is that the Theranostic Pair ventures away from Neuroendocrine Tumors and Prostate Cancer. The recently published article by Michael Hofman et al. shows how a new a new peptide, CAIX, has promise to be the next heavy hitter in the therapeutics space with focus on Clear Cell Renal Cell Carcinoma (ccRCC). Ga-68 labeled CAIX offers a high tumor-to-background ratio in just one hour (much shorter than that of other PET scans that take days to assess). Thanks to the quick clearance rate and high tumor-to-background ratio, this also means that the organ toxicity is minimal. Combined with Lu-177 labeled CAIX, a new way to treat ccRCC may be up-and-coming!   Check out the article here: https://lnkd.in/d3kPbye6

A retrospective study in the Journal of Nuclear Medicine found that patients with oligorecurrent prostate cancer who underwent metastasis-directed therapy guided by PSMA PET/CT had longer progression-free survival, compared with those guided by choline PET/CT. Data showed 49.2% of patients had post-MDT progression in the PSMA PET/CT group, compared with 86.7% of those in the choline PET/CT group